Michael Wang, M.D., Ph.D., Chief Strategy Officer, Author at NFCR

The World’s First Oncolytic Virus Drug was Launched to Treat Malignant Brain Tumor GBM

Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumor in adults, with a median survival of only about ten months. Unlike low-grade gliomas (grades I and II), which grow slowly, high-grade gliomas (grades III and IV) grow much faster and can spread to other parts of the brain, resulting…...

Read more

How Long Can the Immunity Against COVID-19 Protect Us from Reinfection?

There has been major concern about the protective power of immunity against the novel coronavirus. Many people have asked: how long can the immunity, once acquired by the previous infection or vaccination, protect us from the COVID-19 reinfection? In February of 2021, a group of researchers reported that the immunity…...

Read more

Natural Killer (NK) Cell-based Treatment Demonstrates Its Potential to Become an Effective Novel Cancer Therapy

Natural Killer (NK) cells are specialized lymphocytes that play critical roles in the immune response against abnormal cells, including all kinds of cancer cells. Different from T cells that need to be pre-activated by antigen-presenting cells before gaining the killing power, NK cells can quickly respond to a wide variety…...

Read more

Therapeutic Vaccines Showed Long-term Anti-Cancer Effects for Melanoma

When people hear the word “vaccine”, they often think about vaccine’s preventive function that protects people from getting infectious diseases such as flu, hepatitis or Covid-19.  It’s true that traditional vaccines are developed to prevent infectious diseases, but innovative scientists are developing therapeutic vaccines that can treat various non-infectious diseases,…...

Read more